Efficacy and Safety of TACE-HAIC Combined with Molecular Targeted Therapy and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Zhipeng Feng, Xiaolong Wang, Junming Xu, Shiguang Chen, Mingzhi Hao, Hong Hu, Shixiang Qiu, Yunguo Liao, Wenchang Yu, Zhuting Fang · 2026
Read Efficacy and Safety of TACE-HAIC Combined with Molecular Targeted Therapy and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma by Zhipeng Feng, Xiaolong Wang, Junming Xu, Shiguang Chen, Mingzhi Hao, Hong Hu, Shixiang Qiu, Yunguo Liao, Wenchang Yu, Zhuting Fang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13209144.txt.
Description
Adding a second artery-directed treatment may extend survival in inoperable liver cancer, and a 2026 study led by Zhipeng Feng tests that four-part strategy. The research article contrasts 274 patients with unresectable hepatocellular carcinoma who received chemoembolization plus arterial infusion chemotherapy, targeted drugs, and immune checkpoint inhibitors against a triple regimen without the infusion.
After matching the groups on baseline traits, the four-part regimen kept cancer controlled months longer and extended median survival by roughly half a year in the authors' analysis. Tumor shrinkage and disease control rates were also higher with the added infusion step. Side effects stayed manageable in both groups, supporting the combination for wider testing.
Catalog record
| CREATOR | Zhipeng Feng, Xiaolong Wang, Junming Xu, Shiguang Chen, Mingzhi Hao, Hong Hu, Shixiang Qiu, Yunguo Liao, Wenchang Yu, Zhuting Fang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |